Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Changes to Hologic Management; New Hires, Board Members at CareDx, CardioDx

Premium

Hologic this week disclosed that CFO Glenn Muir will be retiring on an unspecified date.

"We are in an active process to bring in a new CFO, and are grateful that Glenn will remain in his role to ensure a seamless transition and continued execution of our financial strategies," Hologic CEO Stephen MacMillan noted during a conference call this week recapping the company's fiscal second quarter earnings.

Muir has held the position of executive vice president of finance and administration since September 2000, and CFO since 1992. Muir served as the company's controller from October 1988 to 1992. He received an MBA from the Harvard Graduate School of Business Administration in 1986.

Hologic also disclosed during the call that Eric Compton has joined the company as chief operating officer, and Claus Egstrand has joined Hologic as senior vice president and general manager, international.

Compton will oversee the day-to-day operations of Hologic's business units, as well as its global R&D and manufacturing efforts, MacMillan noted during the earnings call. He joined Hologic from Johnson & Johnson, where he most recently served as worldwide president of Ortho Clinical Diagnostics.

Egstrand joined Hologic from Merck, and has overseen a variety of international businesses within large organizations over his 30-plus-year career, MacMillan noted.


CareDx (formerly XDx) this week announced the appointment of George Bickerstaff as a member of the Board of Directors.

Bickerstaff is currently a managing director with M.M. Dillon & Co (previously known as CRT Investment Banking) and has held various roles with the company since 2005. Prior to joining CRT Capital Group, Bickerstaff was CFO of Novartis Pharma.


CardioDx said this week that Melinda Griffith has joined the company as head of corporate development and general counsel, while Doug Ross has joined the firm as CSO.

Griffith served in multiple executive management positions at Clarient (now part of GE Healthcare), including senior vice president of business development and product strategy, and general counsel and secretary. She has also served as executive vice president of corporate development and general counsel of Tethys Bioscience, and senior vice president of licensing and law at Roche Molecular Diagnostics. Griffith also held senior corporate counsel roles at Genelabs Technologies, Axys Pharmaceuticals, and Cetus Corporation.

Ross was an independent consultant serving as acting CSO of the medical science division of Life Technologies (now part of Thermo Fisher Scientific). He was also formerly CSO of Clarient. Ross joined Clarient with the merger and acquisition of Applied Genomics, a company he co-founded in 2000 and where he served as CSO.

CardioDx also said that it has appointed James Tobin and Andrew Guggenhime to its board of directors. Guggenhime will be transitioning from his role as CFO of CardioDx, a position he has held since he joined the company in 2011. Tobin previously served as CEO and president of Boston Scientific. Prior to Boston Scientific, he was President of Biogen (now Biogen Idec) and Baxter International. Currently, he serves on the board of Curis and several other private companies.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.